FOXO3 and B-cell non-Hodgkin lymphoma: To support this hypothesis, a further study demonstrated that miR-155 promoted B cell lymphoma cell proliferation and inhibited cell apoptosis through targeting inhibition of FOXO3, and both miR-155 overexpression and FOXO3 low-expression were related to poor prognosis in patients with DLBCL [77, 78].